Phase 1, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery
Sponsor: |
American Association for Cancer Research |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR6735 |
U.S. Govt. ID: |
NCT03572283 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to determine whether the drug, bethanechol, could potentially be used in combination with surgery to decrease the chance of the cancer coming back after it is removed. Bethanechol is a medication that regulates the parasympathetic nervous system and is often used to manage the side effects of chemotherapy drugs and to manage urinary retention. Studies of pancreatic cancer in animal models have shown that treatment with bethanechol can inhibit cancer growth and spread. People with pancreatic cancer localized to a small area usually undergo surgery to remove the tumor.
This study is closed
Investigator
Susan Bates, MD
Are you 18 years or older? |
Yes |
No |
Do you have a confirmed diagnosis of pancreatic ductal adenocarcinoma or are you willing to undergo a biopsy prior to therapy? |
Yes |
No |
Do you have a predicted life expectancy of greater than 3 months? |
Yes |
No |